Virax Biolabs Group 주식 (NASDAQ: VRAX)

에 대한 최신 뉴스 Virax Biolabs Group (NASDAQ:VRAX) 주식

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Broad U.S. Equity ETFs

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

APDN

ASTS

CING

CRWD

GOVX

INDO

LUMN

LUNR

NVDA

PLTR

SERV

SMCI

TSLA

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Virax Biolabs Group Limited - Ordinary Shares

Virax Biolabs Group Ltd

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

News

Price Target

Reiteration

Analyst Ratings

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

Food company Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Friday.
The company has introduced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44323543/pilgrims-announces-1-5-billion-special-dividend-and-long-term-capital-allocation-strategy" rel="noreferrer noopener">capital allocation strategy </a>designed to strengthen its financial position, broaden its diverse portfolio, and generate long-term value for its shareholders.
As a component of this initiative, the board has approved a special cash dividend of $6.30 per share. With the current share count, the total special dividend payout is approximately $1.5 billion.
This payment will be made on April 17, 2025, to shareholders on record as of April 3, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44305204/metas-community-notes-to-replace-third-party-fact-checkers" rel="noreferrer noopener">Meta&#8217;s Community Notes To Replace Third-Party Fact Checkers</a>
&#8220;Pilgrim&#8217;s is confident in the future of our business and we believe our capital allocation strategy positions the company for continued, disciplined growth and enhanced earnings potential across our diversified portfolio,&#8221; said CEO Fabio Sandri.
&#8220;The Board&#8217;s decision to pay a special dividend reflects our strong balance sheet and our commitment to create long-term stockholder value.&#8221;
In addition to the dividend, Pilgrim&#8217;s Pride has outlined steps to further strengthen its business operations.
The company is focusing on key areas such as expanding its prepared foods segment, increasing small bird production for key customer demands, and transforming a major bird facility into a case-ready plant to support retail growth.
Furthermore, Pilgrim&#8217;s plans to boost protein conversion capacity to enhance its product offerings and minimize risk.
Over the past five years, Pilgrim&#8217;s Pride has committed huge capital to various initiatives, including more than $950 million in acquisitions, $1.8 billion in share buybacks and dividends, and $2.2 billion in capital expenditures.
Price Action: PPC shares traded higher by 5.39% at $52.98 in premarket on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44301525/canadian-imperial-bank-picks-harry-culham-as-next-ceo" target="_blank" rel="noreferrer noopener">Canadian Imperial Bank Picks Harry Culham As Next CEO</a></li>
</ul>
Image via Shutterstock.

Equities

Dividends

Movers

General

Why Is Poultry Producer Pilgrim's Pride Stock Surging Today?

Piper Sandler analyst Korinne Wolfmeyer maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and lowers the price target from $425 to $364.

ULTA

Piper Sandler Maintains Neutral on Ulta Beauty, Lowers Price Target to $364

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 10.33%</li>
<li>RBC Capital analyst Michael Carroll maintained an Underperform rating and cut the price target from $12 to $11 on March 10, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and lowered the price target from $14 to $13 on Dec. 6, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 25, Easterly Government Props posted fourth-quarter FFO of 29 cents, in-line with estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DEA <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png" alt="" class="wp-image-824364" style="width:475px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-768x710.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 9.17%</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $15 to $13 on Feb. 3, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Wolfe Research analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Feb. 19, Park Hotels &amp; Resorts posted better-than-expected quarterly revenue.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">latest PK news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png" alt="" class="wp-image-824366" style="width:492px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-768x714.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.60%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and raised the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png" alt="" class="wp-image-824369" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

Needham analyst Quinn Bolton reiterates D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and maintains $8.5 price target.

QBTS

Needham Reiterates Buy on D-Wave Quantum, Maintains $8.5 Price Target

Needham analyst Quinn Bolton reiterates Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and maintains $54 price target.

SMTC

Needham Reiterates Buy on Semtech, Maintains $54 Price Target

Piper Sandler analyst Peter Keith maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Neutral and raises the price target from $79 to $81.

Piper Sandler Maintains Neutral on Dollar Gen, Raises Price Target to $81

Piper Sandler analyst Quinton Gabrielli maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight and lowers the price target from $268 to $200.

MANH

Piper Sandler Maintains Overweight on Manhattan Associates, Lowers Price Target to $200

Needham analyst Chris Pierce reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from Hold to Hold.

BLNK

Needham Reiterates Hold on Blink Chargingto Hold

Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) with a Buy and maintains $8 price target.

GBIO

Needham Reiterates Buy on Generation Bio, Maintains $8 Price Target

AAOI: 92% &#x7C; <a href="https://www.benzinga.com//node/44317133">Applied Optoelectronics shares are trading higher after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.</a>
&nbsp;
SMTC: 13% &#x7C; <a href="https://www.benzinga.com//node/44316016">Semtech shares are trading higher after the company reported better-than-expected Q4 financial results.</a>
&nbsp;
RBRK: 21% &#x7C; <a href="https://www.benzinga.com//node/44315877">Rubrik shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.</a>

AAOI

RBRK

Market-Moving News for March 14th

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) reported stronger-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/ulta/earnings">financial results on Thursday</a>.
Ulta Beauty reported fourth-quarter revenue of $3.49 billion, beating the consensus estimate of $3.46 billion. The specialty beauty retailer reported fourth-quarter earnings of $8.46 per share, beating analyst estimates of $7.14 per share, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
"I am incredibly optimistic about the future of Ulta Beauty, as I believe we have the right elements to drive our success — a strong business model, an ambitious long-term plan, and passionate associates who bring our brand to life for our guests every day," said Kecia Steelman, president and CEO of Ulta Beauty.
Ulta Beauty expects fiscal year 2025 revenue of $11.5 billion to $11.6 billion versus estimates of $11.67 billion, according to Benzinga Pro. The company anticipates full-year earnings of $22.50 to $22.90 per share versus estimates of $23.50 per share.
Ulta Beauty shares fell 4.5% to close at $314.47 on Thursday.
These analysts made changes to their price targets on Ulta Beauty following earnings announcement.
<ul>
<li>Morgan Stanley analyst Simeon Gutman maintained Ulta Beauty with an Overweight rating and lowered the price target from $500 to $460.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained the stock with an Outperform rating and cut the price target from $500 to $460.</li>
</ul>
Considering buying ULTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png" alt="" class="wp-image-824610" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44323490/ulta-beauty-docusign-and-3-stocks-to-watch-heading-into-friday">Ulta Beauty, DocuSign And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Earnings

Ulta Beauty Analysts Slash Their Forecasts After Q4 Results

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $5 price target.

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $5 Price Target

Palantir Technologies Partners With R1 To Launch R37 AI Lab, Revolutionizing Healthcare Financial Performance With Advanced Automation Solutions

Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. The company reported quarterly sales of $137.799 million which beat the analyst consensus estimate of $97.352 million by 41.55 percent. This is a 40.88 percent increase over sales of $97.810 million the same period last year.

Earnings Beats

GOGO

CORRECTION: Gogo Q4 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $137.799M Beat $97.352M Estimate

Needham analyst Chris Pierce maintains Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) with a Buy and lowers the price target from $1.5 to $1.

Needham Maintains Buy on Urgently, Lowers Price Target to $1

Bristol Myers Squibb Says European Commission Granted Approval To Breyanzi For Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma

Wayfair Announces Plans For Second Large-Format Store In Atlanta, Set To Open In 2026, Offering 150,000 Square Feet Of Home Furniture And Decor

Telsey Advisory Group analyst Joseph Feldman maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Outperform and maintains $250 price target.

Telsey Advisory Group Maintains Outperform on Dick's Sporting Goods, Maintains $250 Price Target

IRIX

Iridex Says Not Aware Of Any Material Developments Or Changes To Operating Or Financial Condition For Recent Stock Price Volatility

Contracts

Press Releases

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

COSM

CRDL

DBVT

MODD

AdaptHealth

Akso Health Group - American Depositary Shares

Akso Health

Agape ATP

Cardinal Health

Cencora

Cosmos Health

Henry Schein

McKesson

Owens & Minor

Patterson Cos

Virax Biolabs Group

Wellgistics Health

매일의 거래일에는 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목들</a>에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다.
2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
&#8211; 현재가: $119.37 
&#8211; 52주 범위: $39.23 ~ $140.76 
&#8211; 연초 대비 수익률: +147.8% 
&#8211; <a href="https://www.benzinga.com/news/earnings/23/02/30713474/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-january-where-do-spy-tesla-apple-and-ford" target="_blank" rel="noopener" data-google-interstitial="false">1월</a>/<a href="https://www.benzinga.com/markets/penny-stocks/23/03/31137326/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-february-including-tesla-apple-and" target="_blank" rel="noopener" data-google-interstitial="false">2월</a>/<a href="https://www.benzinga.com/markets/equities/24/04/38023764/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-march-where-do-tesla-nvidia-spy-and-re" target="_blank" rel="noopener" data-google-interstitial="false">3월</a> 검색 순위: 3위/1위/1위 
&#8211; <a href="https://www.benzinga.com/exclusives/24/06/39234936/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-may-where-do-nvidia-tesla-gamestop-amc-ran" target="_blank" rel="noopener" data-google-interstitial="false">5월</a>/<a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a> 검색 순위: 2위/1위/2위
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
&#8211; 현재가: $563.68 
&#8211; 52주 범위: $409.22 ~ $565.22 
&#8211; 연초 대비 수익률: +19.3% 
&#8211; 1월/2월/3월 검색 순위: 2위/2위/3위 
&#8211; 5월/6월/7월 검색 순위: 1위/3위/3위
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
&#8211; 현재가: $214.11 
&#8211; 52주 범위: $138.80 ~ $278.97 
&#8211; 연초 대비 수익률: -13.8% 
&#8211; 1월/2월/3월 검색 순위: 1위/4위/2위 
&#8211; 5월/6월/7월 검색 순위: 4위/4위/1위
4. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
&#8211; 현재가: $437.70 
&#8211; 52주 범위: $226.59 ~ $1,229.00 
&#8211; 연초 대비 수익률: +53.3% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함/상위 20위 미포함/5위 
&#8211; 5월/6월/7월 검색 순위: 14위/10위/19위
5. 루멘 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)
&#8211; 현재가: $5.25 
&#8211; 52주 범위: $0.78 ~ $7.83 
&#8211; 연초 대비 수익률: +17.8% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함 
&#8211; 5월/6월/7월 검색 순위: 상위 20위 미포함
6. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
&#8211; 현재가: $229.00 
&#8211; 52주 범위: $164.08 ~ $237.23 
&#8211; 연초 대비 수익률: +23.4% 
&#8211; 1월/2월/3월 검색 순위: 5위/8위/4위 
&#8211; 5월/6월/7월 검색 순위: 6위/5위/7위
7. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
&#8211; 현재가: $31.48 
&#8211; 52주 범위: $13.68 ~ $33.12 
&#8211; 연초 대비 수익률: +89.9% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함/상위 20위 미포함/11위 
&#8211; 5월/6월/7월 검색 순위: 6위/5위/7위
8. 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
&#8211; 현재가: $148.56 
&#8211; 52주 범위: $93.12 ~ $227.30 
&#8211; 연초 대비 수익률: +7.2% 
&#8211; 1월/2월/3월 검색 순위: 12위/14위/8위 
&#8211; 5월/6월/7월 검색 순위: 8위/9위/4위
9. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
&#8211; 현재가: $476.27 
&#8211; 52주 범위: $342.35 ~ $503.52 
&#8211; 연초 대비 수익률: +18.3% 
&#8211; 1월/2월/3월 검색 순위: 18위/상위 20위 미포함/9위 
&#8211; 5월/6월/7월 검색 순위: 9위/11위/11위
10. 지오백스 랩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>)
&#8211; 현재가: $4.63 
&#8211; 52주 범위: $1.09 ~ $11.18 
&#8211; 연초 대비 수익률: -16.6% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함 
&#8211; 5월/6월/7월 검색 순위: 상위 20위 미포함
주목할 만한 종목들: 다음 주식들은 2024년 상반기에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들이었다.
11. 인도네시아 에너지 코퍼레이션 (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>)
12. 바이랙스 바이오랩스 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>)
13. 아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
14. 싱귤레이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>)
15. 메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
16. 서브 로보틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)
17. 어플라이드 DNA 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>)
18. AST 스페이스모바일 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)
19. 크라우드스트라이크 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)
20. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
중요한 이유 (Why It&#8217;s Important): 엔비디아는 해당 월 동안 <a href="https://www.benzinga.com/news/earnings/24/08/40613050/nvidia-q2-earnings-guidance-top-street-view-as-ai-fuels-record-data-center-revenue-gross-margin-fal" target="_blank" rel="noopener" data-google-interstitial="false">분기별 실적 발표</a>가 있어서 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식이었다. 이 회사는 분석가들의 추정치를 웃돌았고, 추정치보다 앞선 지침을 공유했다. 해당 주식은 올해 매달 Benzinga Pro에서 가장 많이 검색된 상위 3개 종목 중 하나로 꾸준히 선정되었다.
7월 1위를 차지했던 테슬라는 8월 3위로 떨어졌다. 이 전기 자동차 주식은 2024년 동안 매달 가장 많이 검색된 4개 종목 중 하나로 선정되었다.
8월에는 두 개의 ETF가 가장 많이 검색된 종목 중 하나였으며 SPY가 2위, QQQ가 9위를 차지했다. S&amp;P 500을 추적하는 SPY는 매월 가장 많이 검색되는 상위 3개 종목 중 하나로 정기적으로 선정되었다. 나스닥 100을 추적하는 QQQ는 8월 상승세를 보이며 5월 이후 처음으로 다시 톱 10에 진입했다.
슈퍼 마이크로 컴퓨터는 8월에 <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/08/40579899/super-micro-computer-stock-falls-on-short-report-hindenburg-says-company-has-accounting" target="_blank" rel="noopener">공매도 보고서</a>와 회사의 업데이트로 인해 관심이 급증한 것으로 보인다. 지난 3월 5위까지 올랐던 주가는 8월 4위를 기록했다. 주가는 6월 10위 이후 처음으로 다시 10위권 안으로 진입했다.
신규 주식 두 종목이 상위 10개 종목 목록에 합류했으며, 루멘 테크놀로지스는 5위, 지오백스 랩스는 10위를 차지했다. 루멘은 이번 달 <a href="https://www.benzinga.com/news/24/08/40221474/lumen-technologies-stock-continues-to-soar-whats-going-on" target="_blank" rel="noopener">분기별 재무 결과를 발표</a>한 후 주가가 급등하고 투자자들의 관심을 받았다. 지오백스 랩스는 엠폭스(mpox, 원숭이두창)에 대한 세계보건기구(WHO)의 <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal" target="_blank" rel="noopener">긴급 보건 선언</a>과 관련하여 높은 변동성과 관심 증가를 확인했다. 지오백스 랩스에는 엠폭스에 효과적이라고 알려진 백신이 있다.
상위 10위권에는 8월 16위를 차지한 서브 로보틱스와 8월 상위 20위 안에 들지 못한 잽 전기차 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>)이 포함되었다.
iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)는 독자들의 지속적인 관심을 받고 있다. 소형주를 추적하는 이 ETF는 7월 22위에 이어 8월에는 24위에 올랐다. 잠재적인 연방준비제도의 금리 인하가 임박함에 따라 9월에는 소형주와 ETF에 대한 관심이 높아질 수 있다.
Photo created using artificial intelligence via MidJourney.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Virax Biolabs Group

뉴스

에 대한 최신 뉴스 Virax Biolabs Group (NASDAQ:VRAX) 주식

수요일, 9월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌